Medlab Clinical Ltd (ASX: MDC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Medlab Clinical Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$15.07 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
2.28 million
Earnings per share
-547.500
Dividend per share
N/A
Year To Date Return
-1.49%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Medlab Clinical Ltd (ASX: MDC)
Latest News
Healthcare Shares
Why is the Medlab (ASX:MDC) share price surging 8% today?
Share Market News
Here's why the Medlab (ASX:MDC) share price is rising today
Share Gainers
Why Clean TeQ, Medlab, Newcrest, & Ramelius are storming higher today
Share Gainers
Why this ASX cannabis share is shooting 15% higher today
Share Gainers
Why THC Global and these ASX cannabis shares are rocketing higher today
52-Week Highs
Why this ASX biotech is printing 52-week highs
Share Gainers
This small-cap ASX biotech's share price is soaring today
Share Gainers
Why Medlab, Metcash, SKY and Space Global, and WiseTech shares charged higher today
Share Market News
These small cap ASX shares are on the rise today
⏸️ Investing
Is Medlab Clinical Ltd the best small cap healthcare buy on the ASX?
⏸️ Investing
Why these pot stocks are moving higher
⏸️ Investing
Why shares of Medlab Clinical Ltd have risen 37% in 2018
1❯
MDC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Medlab Clinical Ltd
Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Michael Kenneth Carter | Non-Executive Director | Mar 2023 |
Mr Carter is experienced in structuring corporate transactions and has also worked in ongoing corporate advisory roles with numerous ASX listed entities over the last 18 years. Mr Carter has been employed as a stockbroker since 1999 and was previously a director of Indian Ocean Capital. He is currently an associate director of CPS Capital Group and Non-Executive Director of European Lithium Ltd.
|
| Mr Matthew John Hudson | Non-Executive Director | Mar 2023 |
Mr Hudson has experience raising capital for projects based in Africa, Latin America, and Asia. He is a former Credit Suisse and Arthur Andersen advisor, who is now the Co Founder and Managing Director of Hudson Koch Energy. He is also the Founder and Managing Director of United Minerals which operated the historic Potosi Mine in Chihuahua, Mexico.
|
| Mr Sean Michael Hall | Chief Executive OfficerManaging Director | Apr 2014 |
Dr Hall has over 20 years experience in the Australian Healthcare and food industries and early phase drug discovery in Australia and Asia. Sean is best known for building Australia's leading practitioner brand, BioCeuticals. Dr Hall is an active member of Medicines Australia, American Federation for Medical Research, American Academy of Anti-Ageing Medicine, Ausbiotech, a member of the Scientific Advisory Board for BITs Life Science China and a Board Member of the International Probiotics Association.
|
| Mr Kerem Kaya | Chief Financial OfficerCompany Secretary | May 2021 |
-
|
| Kerem Kaya | Chief Financial OfficerCompany Secretary |
-
|
|
| Ian Curtinsmith | Chief Information Officer |
-
|
|
| Luis Vitetta | Director of Medical Research |
-
|
|
| David Rutolo | Director of Science |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Sean Michael Hall | 386,838 | 16.94% |
| Farjoy Pty Ltd | 205,663 | 9.01% |
| HSBC Custody Nominees (Australia) Limited | 106,111 | 4.65% |
| UBS Nominees Pty Ltd | 85,316 | 3.74% |
| Fit Investments Pty Ltd <Hallab Investment A/C> | 75,563 | 3.31% |
| BNP Paribas Nominees Pty Ltd | 73,787 | 3.23% |
| Realm Group Pty Ltd | 70,000 | 3.07% |
| Richard Albarran <Albarran Family No 2 A/C> | 37,038 | 1.62% |
| Rolay Pty Ltd | 37,038 | 1.62% |
| United Trolley Collections P/L | 32,970 | 1.44% |
| Mr Michael Jack Hall + Mrs Elizabeth Ann Jones <Hall Jones Super Fund A/C> | 29,820 | 1.31% |
| Citicorp Nominees Pty Limited | 21,193 | 0.93% |
| Villamagna Inc | 20,000 | 0.88% |
| Netwealth Investments Limited | 18,839 | 0.83% |
| Acron Holdings Pty Limited <Acron Super Fund A/C> | 16,181 | 0.71% |
| Assumo (Nominees) Pty Ltd <Assumo Super Fund A/C> | 13,334 | 0.58% |
| D J Fairfull Pty Ltd <Fairfull Super Fund A/C> | 12,651 | 0.55% |
| Miss Xiaodan Fu | 11,902 | 0.52% |
| Deni Freighters Super Fund Pty Ltd <Deniliquin Freighters Super Fund A/C> | 10,001 | 0.44% |
| Daniel P Moses (Nominees) Pty Ltd <Daniel Moses Family A/C> | 10,000 | 0.44% |
